Sublingual vaccination with influenza virus protects mice against lethal viral infection

[sharon sanders]

[SIZE=-2]IMMUNOLOGY[/SIZE]
[SIZE=+2] Sublingual vaccination with influenza virus protects mice against lethal viral infection[/SIZE]
<nobr>Joo-Hye Song^*<sup>,

</sup></nobr>, <nobr>Huan H. Nguyen<sup>

</sup></nobr>, <nobr>Nicolas Cuburu<sup>

</sup>^,?</nobr>, <nobr>Taisuke Horimoto^||</nobr>, <nobr>Sung-Youl Ko^*</nobr>, <nobr>Se-Ho Park<sup>

</sup></nobr>, <nobr>Cecil Czerkinsky<sup>

</sup></nobr>, and <nobr>Mi-Na Kweon^*^,**</nobr>
*Mucosal Immunology Section, <sup>

</sup>Viral Immunology Section, <sup>

</sup>Laboratory Science Division, International Vaccine Institute, Seoul 151-818, Korea; ^?Institut National de la Sant? et de la Recherche M?dicale U721, Universit? de Nice-Sophia Antipolis, 06107 Nice, France; ^||Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; and <sup>

</sup>Laboratory of Molecular Immunology, School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea
Edited by Roy Curtiss III, Arizona State University, Tempe, AZ, and approved December 12, 2007 (received for review September 13, 2007)
[SIZE=+1]Abstract[/SIZE]
We assessed whether the sublingual (s.l.) route would be aneffective means of delivering vaccines against influenza virusin mice by using either formalin-inactivated or live influenzaA/PR/8 virus (H1N1). Sublingual administration of inactivatedinfluenza virus given on two occasions induced both systemicand mucosal antibody responses and conferred protection againsta lethal intranasal (i.n.) challenge with influenza virus. Coadministrationof a mucosal adjuvant (mCTA-LTB) enhanced these responses andresulted in complete protection against respiratory viral challenge.In addition, s.l. administration of formalin-inactivated A/PR/8plus mCTA-LTB induced systemic expansion of IFN-

-secreting Tcells and virus-specific cytotoxic T lymphocyte responses. Importantly,a single s.l. administration of live A/PR/8 virus was not pathogenicand induced protection mediated by both acquired and innateimmunity. Moreover, s.l. administration of live A/PR/8 virusconferred heterosubtypic protection against respiratory challengewith H3N2 virus. Unlike the i.n. route, the A/PR/8 virus, whetherlive or inactivated, did not migrate to or replicate in theCNS after s.l. administration. Based on these promising findings,we propose that the s.l. mucosal route offers an attractivealternative to mucosal routes for administering influenza vaccines.

[SIZE=-1]intranasal | mucosal adjuvant | mucosal immunity | redirection | secretory IgA[/SIZE]


[SIZE=-1]http://www.pnas.org/cgi/content/abstract/0708684105v1[/SIZE]


[SIZE=-1]
[/SIZE]